KR102710067B1 - 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 - Google Patents

림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 Download PDF

Info

Publication number
KR102710067B1
KR102710067B1 KR1020187037834A KR20187037834A KR102710067B1 KR 102710067 B1 KR102710067 B1 KR 102710067B1 KR 1020187037834 A KR1020187037834 A KR 1020187037834A KR 20187037834 A KR20187037834 A KR 20187037834A KR 102710067 B1 KR102710067 B1 KR 102710067B1
Authority
KR
South Korea
Prior art keywords
antibody
nivolumab
administered
lymphoma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037834A
Other languages
English (en)
Korean (ko)
Other versions
KR20190008962A (ko
Inventor
베네데토 파르사치
네일 조지프슨
앤서니 카오
라이언 헤이저
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
씨젠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102710067(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니, 씨젠 인크. filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020237026623A priority Critical patent/KR20230119265A/ko
Priority to KR1020247031531A priority patent/KR20240145059A/ko
Publication of KR20190008962A publication Critical patent/KR20190008962A/ko
Application granted granted Critical
Publication of KR102710067B1 publication Critical patent/KR102710067B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187037834A 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 Active KR102710067B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020237026623A KR20230119265A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
KR1020247031531A KR20240145059A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662344866P 2016-06-02 2016-06-02
US62/344,866 2016-06-02
US201662382839P 2016-09-02 2016-09-02
US62/382,839 2016-09-02
PCT/US2017/035521 WO2017210473A1 (en) 2016-06-02 2017-06-01 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020247031531A Division KR20240145059A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
KR1020237026623A Division KR20230119265A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도

Publications (2)

Publication Number Publication Date
KR20190008962A KR20190008962A (ko) 2019-01-25
KR102710067B1 true KR102710067B1 (ko) 2024-09-26

Family

ID=59067913

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187037834A Active KR102710067B1 (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
KR1020237026623A Ceased KR20230119265A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
KR1020247031531A Ceased KR20240145059A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237026623A Ceased KR20230119265A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
KR1020247031531A Ceased KR20240145059A (ko) 2016-06-02 2017-06-01 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도

Country Status (20)

Country Link
US (2) US11299543B2 (cg-RX-API-DMAC7.html)
EP (2) EP3464368B1 (cg-RX-API-DMAC7.html)
JP (3) JP7641704B2 (cg-RX-API-DMAC7.html)
KR (3) KR102710067B1 (cg-RX-API-DMAC7.html)
CN (1) CN109476752A (cg-RX-API-DMAC7.html)
AU (2) AU2017274444B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074619A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026246A1 (cg-RX-API-DMAC7.html)
DK (1) DK3464368T3 (cg-RX-API-DMAC7.html)
ES (1) ES2951650T3 (cg-RX-API-DMAC7.html)
FI (1) FI3464368T3 (cg-RX-API-DMAC7.html)
HU (1) HUE063911T2 (cg-RX-API-DMAC7.html)
IL (1) IL263165A (cg-RX-API-DMAC7.html)
MX (2) MX390955B (cg-RX-API-DMAC7.html)
NZ (1) NZ748650A (cg-RX-API-DMAC7.html)
PL (1) PL3464368T3 (cg-RX-API-DMAC7.html)
PT (1) PT3464368T (cg-RX-API-DMAC7.html)
SG (2) SG10202101062YA (cg-RX-API-DMAC7.html)
SI (1) SI3464368T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017210473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
MX390955B (es) 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
WO2019075188A1 (en) * 2017-10-13 2019-04-18 Seattle Genetics, Inc. MODULATION OF IMMUNE RESPONSE USING CONJUGATES ANTIBODY-MEDICINE
EP3737696A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
SG11202010993VA (en) * 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3902838A4 (en) 2018-12-26 2022-12-21 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
CA3164124A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
CN111407894B (zh) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物
IL298155A (en) * 2020-05-13 2023-01-01 Seagen Inc Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CA3211463A1 (en) 2021-03-01 2022-09-09 Nantbio, Inc. Anti-cd30 monoclonal antibodies and chimeric antigen receptors
CN118987233A (zh) * 2024-08-08 2024-11-22 武汉科技大学 治疗经典型霍奇金淋巴瘤的药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213795A1 (en) 2002-12-23 2004-10-28 Wyeth Antibodies against PD-1 and uses therefor
US20060110383A1 (en) 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1210428E (pt) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014124227A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
EP3521312B1 (en) * 2013-02-20 2021-04-07 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
WO2015088847A1 (en) * 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
PL3463457T3 (pl) 2016-06-02 2023-08-21 Bristol-Myers Squibb Company Blokada pd-1 niwolumabem w opornym chłoniaku hodgkina
MX390955B (es) 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110383A1 (en) 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
US20090297518A1 (en) 2002-07-03 2009-12-03 Tasuku Honjo Immunopotentiative composition
US20040213795A1 (en) 2002-12-23 2004-10-28 Wyeth Antibodies against PD-1 and uses therefor
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood, 138(6), 427-438(2021.)
EUROPEAN JOURNAL OF HAEMATOLOGY, 97(3), 219-227(2016.05.30.) 1부.*
NCT01896999(2016.05.10.) 1부.*
NEW ENGLAND JOURNAL OF MEDICINE, 372(4), 311-319(2014.12.06.) 1부.*

Also Published As

Publication number Publication date
JP2024020202A (ja) 2024-02-14
EP4248989A2 (en) 2023-09-27
EP3464368B1 (en) 2023-06-28
PT3464368T (pt) 2023-08-17
IL263165A (en) 2018-12-31
JP2019517505A (ja) 2019-06-24
KR20240145059A (ko) 2024-10-04
US11299543B2 (en) 2022-04-12
MX2022003571A (es) 2022-04-25
BR112018074619A2 (pt) 2019-03-06
NZ748650A (en) 2025-11-28
AU2017274444B2 (en) 2024-08-01
SG10202101062YA (en) 2021-03-30
MX390955B (es) 2025-03-19
EP4248989A3 (en) 2023-12-27
DK3464368T3 (da) 2023-10-02
AU2024227762A1 (en) 2024-11-21
ES2951650T3 (es) 2023-10-24
EP3464368A1 (en) 2019-04-10
JP2022176973A (ja) 2022-11-30
US20190218293A1 (en) 2019-07-18
MX2018014610A (es) 2019-02-28
SI3464368T1 (sl) 2023-10-30
US20220298243A1 (en) 2022-09-22
WO2017210473A1 (en) 2017-12-07
KR20190008962A (ko) 2019-01-25
HUE063911T2 (hu) 2024-02-28
FI3464368T3 (fi) 2023-09-12
AU2017274444A1 (en) 2018-12-13
CA3026246A1 (en) 2017-12-07
SG11201810454YA (en) 2018-12-28
PL3464368T3 (pl) 2023-08-28
CN109476752A (zh) 2019-03-15
KR20230119265A (ko) 2023-08-16
JP7641704B2 (ja) 2025-03-07

Similar Documents

Publication Publication Date Title
KR102710067B1 (ko) 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
US20250026831A1 (en) Methods of treating colorectal cancer
US20180319892A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP7568698B2 (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
EP4386005A2 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
KR102634093B1 (ko) 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
NZ788322A (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
EA046895B1 (ru) Способ и набор для лечения субъекта, страдающего от опухоли, происходящей из неходжкинской лимфомы, или опухоли, происходящей из лимфомы ходжкина
EP4423135A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001691; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230803

Effective date: 20240531

PJ1301 Trial decision

Decision date: 20240531

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2018 7037834

Appeal request date: 20230803

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023101001691

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 198

St.27 status event code: A-4-4-G10-G15-tad-PA0102

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 199